CAR T-cells for lupus and myositis
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment using your own immune cells (CAR T-cells) targeted at a marker called CD19. It is for people whose lupus or myositis has not been controlled by other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have either lupus (SLE) for at least 6 months or a muscle inflammation called IIM (myositis).
- Your lupus or myositis has not improved with standard treatments or has come back.
- You have a positive test for CD19 markers on your immune cells.
- You do not have active infections like hepatitis or tuberculosis.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell treatment (BCMA-CD19 cCAR T cells) for people with lupus that has not responded well to standard therapies. It may help reduce lupus disease activity.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune rheumatic diseases like rheumatoid arthritis, lupus, or scleroderma that have not responded well to standard treatments. The therapy works by modifying your own immune cells to help control the disease.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.